Cargando…

Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment

Objective: The purpose of this health technology assessment (HTA), commissioned by the German Agency for HTA at the German Federal Ministry of Health and Social Security, was to systematically review the evidence on effectiveness and cost-effectiveness of antiviral treatment (AVT) for initial chroni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siebert, Uwe, Sroczynski, Gaby
Formato:	Texto
Lenguaje:	English
Publicado:	German Medical Science 2003
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703229/ https://www.ncbi.nlm.nih.gov/pubmed/19675705

Ejemplares similares

Decision-analytic modeling for early health technology assessment of medical devices – a scoping review
por: Conrads-Frank, Annette, et al.
Publicado: (2022)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Investigation of Factors Considered by Health Technology Assessment Agencies in Eight Countries
por: Yuasa, Akira, et al.
Publicado: (2020)

Using decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German health care system
por: Siebert, Uwe
Publicado: (2005)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop
por: Elvidge, Jamie, et al.
Publicado: (2021)

The Role of decision-analytic modelling in German health technology assessments
por: Kuhlmann, Alexander, et al.
Publicado: (2015)

Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"
por: Goetghebeur, Mireille, et al.
Publicado: (2020)

Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
por: Kwon, Jung Hyun, et al.
Publicado: (2009)

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
por: Witthöft, Th, et al.
Publicado: (2007)

Methods of international health technology assessment agencies for economic evaluations- a comparative analysis
por: Mathes, Tim, et al.
Publicado: (2013)

HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: A SURVEY OF NON-EUROPEAN UNION AGENCIES
por: Ciani, Oriana, et al.
Publicado: (2015)

Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe
por: Oortwijn, Wija, et al.
Publicado: (2019)

Exploring the COVID-19 Pandemic’s Impact on the Health Technology Assessment Process of the National Commission for the Incorporation of Technologies Into the Brazilian Health System
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2023)

Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
por: Hallsson, Lára R., et al.
Publicado: (2023)

A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies
por: Hoxhaj, Ilda, et al.
Publicado: (2020)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials
por: Aminizadeh, Ehsan, et al.
Publicado: (2016)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
por: Yu, Ming-Lung, et al.
Publicado: (2012)

Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C
por: Masaki, Naohiko, et al.
Publicado: (2014)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
por: Ide, Kazuki, et al.
Publicado: (2016)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy
por: Kanda, Tatsuo, et al.
Publicado: (2012)

Hospital-based health technology assessment: the next frontier for health technology assessment
por: Sampietro-Colom, Laura, et al.
Publicado: (2017)

Comparison of tools for assessing the methodological quality of primary and secondary studies in health technology assessment reports in Germany
por: Dreier, Maren, et al.
Publicado: (2010)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
por: Mühlberger, Nikolai, et al.
Publicado: (2009)

Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants
por: Seidl, Astrid, et al.
Publicado: (2018)

HTA Agencies Need Evidence-Informed Deliberative Processes Comment on "Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"
por: Schlander, Michael
Publicado: (2020)

Sarcoidosis with Both Plaques and Subcutaneous Nodules Associated with Combination Therapy with Peginterferon α-2a and Ribavirin
por: Kondo, M., et al.
Publicado: (2011)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
por: Jeong, Seok Hoo, et al.
Publicado: (2012)

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
por: Yan, Zehui, et al.
Publicado: (2012)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
por: Kuo, Ming-Te, et al.
Publicado: (2014)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
por: Yang, Zongguo, et al.
Publicado: (2013)

Health Technology Assessment in Osteoporosis
por: Hiligsmann, Mickael, et al.
Publicado: (2013)

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Real World Data in Health Technology Assessment of Complex Health Technologies
por: Hogervorst, Milou A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cqb4cmgqb99ppisbp1cok281gq